Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Miles

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Cancer|May 14, 2005
Capecitabine plus docetaxel combination therapyShailendra Verma, Dominique Maraninchi, Joyce O'Shaughnessy, et al.
Transfusion|April 25, 2015
Implementation of a clinical decision support system improves compliance with restrictive transfusion policies in hematology patientsCaroline E Butler, Simon Noel, Stephen P Hibbs, et al.
The Oncologist|May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRASandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.
Molecular and Cellular Biology|August 2, 2012
Sequential eukaryotic translation initiation factor 5 (eIF5) binding to the charged disordered segments of eIF4G and eIF2β stabilizes the 48S preinitiation complex and promotes its shift to the initiation modeChingakham Ranjit Singh, Ryosuke Watanabe, Wasimul Chowdhury, et al.
Clinical Breast Cancer|October 28, 2004
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trialDavid Miles, Svetislava Vukelja, Vladimir Moiseyenko, et al.
Digestive Diseases and Sciences|February 9, 2020
Spontaneous Flares of Chronic Hepatitis B Virus in Hepatitis Be Antigen Negative Carriers Who Subsequently Clear Hepatitis B Surface AntigenDaniel Iluz-Freundlich, Nabeel Samad, David Miles, et al.
The Journal of Infectious Diseases|April 22, 2008
Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The GambiaSteve Kaye, David Miles, Pierre Antoine, et al.
The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.
BMC Cancer|April 7, 2018
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsLouise Hiller, Janet A Dunn, Shrushma Loi, et al.
The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trialVéronique Diéras, David Miles, Sunil Verma, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Cancer|May 14, 2005
Capecitabine plus docetaxel combination therapyShailendra Verma, Dominique Maraninchi, Joyce O'Shaughnessy, et al.
Transfusion|April 25, 2015
Implementation of a clinical decision support system improves compliance with restrictive transfusion policies in hematology patientsCaroline E Butler, Simon Noel, Stephen P Hibbs, et al.
The Oncologist|May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRASandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.
Molecular and Cellular Biology|August 2, 2012
Sequential eukaryotic translation initiation factor 5 (eIF5) binding to the charged disordered segments of eIF4G and eIF2β stabilizes the 48S preinitiation complex and promotes its shift to the initiation modeChingakham Ranjit Singh, Ryosuke Watanabe, Wasimul Chowdhury, et al.
Clinical Breast Cancer|October 28, 2004
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trialDavid Miles, Svetislava Vukelja, Vladimir Moiseyenko, et al.
Digestive Diseases and Sciences|February 9, 2020
Spontaneous Flares of Chronic Hepatitis B Virus in Hepatitis Be Antigen Negative Carriers Who Subsequently Clear Hepatitis B Surface AntigenDaniel Iluz-Freundlich, Nabeel Samad, David Miles, et al.
The Journal of Infectious Diseases|April 22, 2008
Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The GambiaSteve Kaye, David Miles, Pierre Antoine, et al.
The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.
BMC Cancer|April 7, 2018
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsLouise Hiller, Janet A Dunn, Shrushma Loi, et al.
The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trialVéronique Diéras, David Miles, Sunil Verma, et al.
Pageof 6